NATO to Hear Hibernation Therapeutics' Life-Saving Research.
ATLANTA -- Professor Geoffrey Dobson, Chief Science Officer, Hibernation Therapeutics, has been asked to address NATO's top medical advisors about his research with Adenocaine([R]) technology that can potentially save lives in far forward locations on the battlefield. He has been invited by the NATO Allied Command Operations Medical Advisor to speak about "Emerging Research in Trauma Care" at Europe top defense organization's Operations Medical Conference in Madrid later this month (March 28-31).
In the Heart Research Laboratory at James Cook University, Professor Dobson has developed a small-volume pharmacological intravenous (IV) solution to rescue and stabilize the heart following massive blood loss and shock. "The laboratory results are so dramatic, that if we can translate our findings onto the battlefield and save soldiers' lives, then we are compelled to do so," Professor Dobson said.
The work, that has been carried out by Dr. Dobson and MSc student Ms. Hayley Letson, won a highly competitive and prestigious award in Trauma at the 2010 Resuscitation Science Symposium at the American Heart Association (AHA) in Chicago. "On the battlefield, catastrophic hemorrhage is the leading cause of preventable death," Professor Dobson said. "In combat situations, up to 50 percent of deaths occur from blood loss, and 25 percent of these may be salvageable.
"The huge problem facing military medical operations is that the majority of combat deaths - up to 90 percent - occur within the first hour after the initial injury." Professor Dobson said the new enemy was time and every second counted. "A massive blood loss of 60 percent and a fall in blood pressure below 50 mmHg rapidly induces shock and carries a risk of death of 95 percent in about 15 minutes."
He said that there was an urgent military need for a pharmacological resuscitation fluid that was lightweight, safe, easy-to-use and promptly stabilized the heart and circulatory system of the severely wounded.
He said there are at least three tactical windows of care where urgent help is needed:
* 'Care under fire' known as the platinum first five to 10 minutes;
* 'Tactical field care' encompassing the Golden Hour; and,
* 'Combat casualty evacuation care' which lasts a number of hours until more definitive surgical care and triage is available by air, land or sea.
Professor Dobson said that he had met Major General Paul Alexander AO, Surgeon General of the Australian Defence Force, and his team in Canberra last month, and they endorsed his presentation to NATO. "They have also agreed to continue discussions about how to fast track the Adenocaine([R]) technology project to help soldiers on the battlefield where nothing else works."
The new battlefield resuscitation strategy is about slowing biological time, an idea that was borrowed from the "tricks" of natural hibernators, and is based on Professor Dobson's prior research innovation, Adenocaine([R]) technology, which is now used in the USA in cardiac surgery, and soon to be introduced in Europe and other international markets.
"By injecting a tiny 'bolus' volume of the battlefield resuscitation fluid comprising a high salt solution (7.5% NaCl), Adenocaine([R]) solution and magnesium into the vein or bone of the critically wounded, the heart powers up and stabilizes the soldier," Dr. Dobson said. "A stronger heart means that you can gently raise the blood pressure into a permissive range that nourishes the vital organs with blood but is not high enough to disrupt the clot, and cause further bleeding and death.
"The other standout feature of the new strategy is to lower whole body oxygen consumption, like a natural hibernator. This is the goal," Professor Dobson said, "to rapidly restore a better supply and demand balance in a life threatening situation. Small-volume hypertonic Adenocaine([R]) therapy has the potential to revolutionize Tactical Combat Casualty Care."
At the NATO conference, Professor Dobson will also present his laboratory's more recent findings on placing a rat in "suspended animation" or a "hibernating-like" state for a finite time period with full and spontaneous recovery of cardiac function. "This far-reaching work has translated into pigs and is being carried out in the USA in collaboration with the cardiothoracic surgery laboratory at Emory University."
Professor Dobson said that inducing a hibernating-like state may also have major clinical and military applications, in addition to his small-volume resuscitation fluid. "The new small-volume resuscitation capability is about saving soldiers' lives through rapid rescue, stabilization and buying time," he said.
"These studies are the first of a series that represent an exciting convergence between our Adenocaine([R]) technology in cardiac surgery and resuscitation science," said David C. Field, Chief Executive Officer for Hibernation Therapeutics. He further stated, "Rescuing and stabilizing the heart following major trauma is an important area of future investigation."
For more information on Hibernation Therapeutics, its Adenocaine([R]) technology and future research, please visit www.Adenocaine.com.
Adenocaine is a registered trademark of Hibernation Therapeutics Global, Ltd.
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 21, 2011|
|Previous Article:||Hitachi Data Systems Appoints Michael Vath as Senior Vice President Global Business Innovation.|
|Next Article:||Bytemobile Secures Its 36th Video Optimization Win for Mobile Network Operator Deployment.|